Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxia
Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxia
批准号:
8100621
负责人:
Min Hee Kang
金额:
$44.44万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-01 至 2014-02-28
关键词:
Acute Lymphocytic LeukemiaAdolescentAerobicAffectAirApoptosisBiochemical PathwayBiological AssayBiological PreservationBone MarrowCancer BiologyCancer cell lineCell Culture TechniquesCell LineCell ProliferationCellsChildChildhoodChildhood Acute Lymphocytic LeukemiaConsumptionCultured CellsDataDexamethasoneDiagnosisDrug CombinationsDrug Delivery SystemsEnzymesFlow CytometryGene ExpressionGene ProteinsGenesGlucocorticoidsGlucoseGlycolysisGoalsGrowthHypoxiaImmunocompromised HostImmunosuppressionIn VitroIncidenceLaboratoriesMalignant NeoplasmsMalignant lymphoid neoplasmMetabolic PathwayMetabolismMitochondriaMolecular ProfilingMusNOD/SCID mouseNon-MalignantOncogenicOxidative PhosphorylationOxygenOxygen measurement, partial pressure, arterialPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPreclinical TestingProductionProliferatingRNARegulationRegulatory PathwayRelapseResearch PersonnelSamplingShort Tandem RepeatSignal PathwaySirolimusStudy modelsSurface AntigensTestingTherapeuticTimeUnited StatesWarburg EffectWestern BlottingXenograft ModelXenograft procedureaerobic glycolysisasparaginasebasecancer cellcytotoxicitydensitydrug sensitivityestablished cell linegenome-wideglucose metabolismhuman FRAP1 proteinin vitro Modelin vitro testingin vivoinhibitor/antagonistleukemiamTOR Inhibitornovelpre-clinicalprogramsrepositoryresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The majority of cancers employ an elevated level of glycolysis, even under mildly aerobic conditions. This bias towards aerobic glycolysis, known as the Warburg effect, is a hallmark of cancer that regulates various cellular attributes including drug sensitivity. Many studies show that the major pathway regulating glycolysis is PI3K/Akt/mTOR pathway. We hypothesize that cancer cell lines established in physiological hypoxia can more accurately mimic leukemia in vivo, and that in vitro studies in physiological O2 of agents targeting the PI3K/Akt/mTOR Pathway in ALL will more closely resemble in vivo results. Our goals are 1) to show that the glycolytic pathway genes are affected by oxygen conditions in acute lymphoblastic leukemia (ALL) established in different oxygen conditions and therefore, the more glucose consumption and more lactate production are seen in cell lines established in hypoxia; and 2) using the cell lines established in hypoxia and direct xenografts we will evaluate drugs targeting the glycolytic pathway. By comparing new childhood acute lymphoblastic leukemia cell lines in atmospheric (20% O2) and physiologic bone marrow (5% O2) oxygen concentrations, we will demonstrate that atmospheric oxygen tension inhibits glycolysis-related gene expression, glucose consumption, lactate production, cell proliferation, and alters dug sensitivities. The effects of physiological and non-physiological (i.e. "standard" culture conditions) oxygen concentrations on glycolysis are not readily reversible by switching cell cultures from one oxygen condition to another, indicating the need to establish cell lines in physiological oxygen conditions in order to provide accurate in vitro models for studying cancer cell metabolism. Our preliminary observations suggest that preservation of the Warburg effect in leukemia requires culturing cells at physiologic oxygen concentrations from the time of their initial establishment. By establishing and evaluating a large panel of leukemia cell lines in two different oxygen conditions, and also for comparison as direct xenografts in immunocompromised mice, we will provide an understanding on the importance of culture conditions on metabolic networks in cancer in vitro models. In addition, we will evaluate whether glycolytic pathway could provide feasible targets for ALL treatment by evaluating new PI3K inhibitor with less immunosuppression in combination with current therapy of ALL (e.g. dexamethasone and L-asparaginase, another metabolism inhibitor). This project will also make available for other investigators via the COG repository (www.COGcell.org) a unique set of well characterized and validated laboratory models for studying cancer biology and preclinical therapeutics.
PUBLIC HEALTH RELEVANCE: Lymphoid malignancies are the most common cancer in children and adolescents in the United States, and the most prevalent of these is acute lymphoblastic leukemia (ALL) with the incidence being gradually increasing over the last 25 years. Significant improvements in primary therapy for childhood ALL have led to an overall cure rate of approximately 80 %. However, of the 20% of patients who relapse, the majority die. The ultimate goals of our proposal are to identify how leukemia cells make energy to grow and proliferate, and to find drugs that can attack the energy generating mechanisms of leukemia cells.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.leukres.2011.10.022
发表时间:
2012-03
期刊:
Leukemia research
影响因子:
2.7
作者:
[Zhang C, Ryu YK, Chen TZ, Hall CP, Webster DR, Kang MH]
通讯作者:
Kang MH
DOI:
10.1158/1078-0432.ccr-15-0114
发表时间:
2016-02-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Hall CP, Reynolds CP, Kang MH]
通讯作者:
Kang MH
Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.
通过在生理氧浓度下建立新的急性淋巴细胞白血病细胞系来保留高糖酵解表型。
DOI:
10.1016/j.yexcr.2015.03.024
发表时间:
2015
期刊:
Experimental cell research
影响因子:
3.7
作者:
[Sheard,MichaelA, Ghent,MatthewV, Cabral,DanielJ, Lee,JoanneC, Khankaldyyan,Vazgen, Ji,Lingyun, Wu,SamuelQ, Kang,MinH, Sposto,Richard, Asgharzadeh,Shahab, Reynolds,CPatrick]
通讯作者:
Reynolds,CPatrick
MYC activation in tumor progression of neuroblastoma
-
批准号:10323261
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
MYC activation in tumor progression of neuroblastoma
-
批准号:10555259
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
MYC activation in tumor progression of neuroblastoma
-
批准号:10064998
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2019
-
负责人:Min Hee Kang
-
依托单位:
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
-
批准号:9143716
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2013
-
负责人:Min Hee Kang
-
依托单位:
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
-
批准号:8501847
-
项目类别:
-
资助金额:$28.41万
-
财政年份:2013
-
负责人:Min Hee Kang
-
依托单位:
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
-
批准号:8664817
-
项目类别:
-
资助金额:$27.55万
-
财政年份:2013
-
负责人:Min Hee Kang
-
依托单位:
海外基金